Brief: D&D Pharmatech Completes Patient Enrollment For Phase 2 Trial Of Dd01
03/02/2025 12:09
Feb 3 (Reuters) - DND Pharmatech Inc 347850.KQ :
* D&D PHARMATECH ANNOUNCES COMPLETION OF PATIENT ENROLLMENT
FOR A
48-WEEK PHASE 2 TRIAL EVALUATING THE EFFECTIVENESS OF DD01, A
LONG-ACTING, DUAL GLP-1/GLUCAGON RECEPTOR AGONIST, IN THE
TREATMENT OF MASH
* DND PHARMATECH INC - TOP-LINE 12-WEEK RESULTS TO BE
ANNOUNCED IN
LATE Q2 2025
Source text: ID:nBw8mpS2Qa
Further company coverage: 347850.KQ
((Reuters.Briefs@thomsonreuters.com;))